Kyntra Bio (NASDAQ:KYNB) Stock Rating Lowered by Wall Street Zen

Kyntra Bio (NASDAQ:KYNB) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other research analysts also recently commented on the stock. HC Wainwright raised shares of Kyntra Bio to a “strong-buy” rating in a research note on Friday, February 27th. Zacks Research lowered Kyntra Bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Finally, Weiss Ratings initiated coverage on shares of Kyntra Bio in a report on Wednesday, January 14th. They set a “sell (d+)” rating for the company. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold”.

Kyntra Bio Stock Performance

Kyntra Bio stock opened at $7.13 on Friday. The firm’s fifty day moving average is $7.74. Kyntra Bio has a fifty-two week low of $4.85 and a fifty-two week high of $12.60. The stock has a market cap of $28.88 million, a PE ratio of 0.16 and a beta of 0.84.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.